Why Catamaran Is Poised to Sail Ahead

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmacy benefits manager Catamaran (NASDAQ: CTRX  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Catamaran and see what CAPS investors are saying about the stock right now.

Catamaran facts

Headquarters (founded)	Lisle, Ill. (1993)
Market Cap	$10.8 billion
Industry	Healthcare services
Trailing-12-Month Revenue	$8.0 billion
Management	Chairman/CEO Mark Thierer (since 2012) CFO Jeffrey Park (since 2012)
Return on Equity (average, past 3 years)	10.3%
Cash/Debt	$393.0 million / $1.3 billion
Competitors	Caremark Pharmacy Services Cerner Express Scripts

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 95% of the 362 members who have rated Catamaran believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, All-Star echofarmer, took a cautiously bullish stance on Catamaran: "Good cash flow and earnings growth history. The main financial con as I see it is the razor thin [profit margins]. Yikes! Not much room for error here, but good cash position to survive any missteps."

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Catamaran may not be your top choice.

Express Scripts shares took a massive dive after a recent earnings report, but has the company's long-term outlook really changed, or is this a classic example of Wall Street being blinded by its short-term lens? In this brand new premium report on Express Scripts, Stock Advisor analyst Jim Mueller dives deep into the company's prospects. Claim your copy today by clicking here now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.